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Allogeneic Hematopoietic Stem Cell Transplant Is
Associated with a Cytomegalovirus Reactivation
and Shows an Indolent Outcome
Sabine Nann-R€utti,1 Alexander Tzankov,2 Nathan Cantoni,1 J€org Halter,1
Dominik Heim,1 Dimitrios Tsakiris,1 Caroline Arber,1 Andreas Buser,1
Alois Gratwohl,1 Andre Tichelli,1 Alicia Rovo1Expansions of CD31 large granular lymphocytes (LGLs) after allogeneic hematopoietic stem cell transplan-
tation (HSCT) have been described. We sought to evaluate incidence, characteristics, and clinical signifi-
cance of persistent T cell (T-)LGL after HSCT. Fourteen of 215 recipients (7%) were diagnosed with LGL
expansions. Thirteen showed a CD31/CD81 immunophenotype, 5 of them with clonal TCR-g
rearrangement. The lymphocytes appeared at a median of 16 months (range, 3-58 months) after HSCT
and lasted for a median time of 31 months (range, 2-179 months). Cytomegalovirus (CMV) reactivation
(P 5 .001) and acute graft-versus-host disease (aGVHD) were associated with LGL expansion (P 5 .02).
In the multivariate analysis, only CMV reactivation showed a significant association with T-LGL expansion
(relative risk [RR]: 5.063; 95% confidence interval [CI]: 1.586-16.160; P 5 .006). The observed posttrans-
plantation LGL expansions, even if monoclonal, showed a chronic, indolent course. Our data indicate
that such expansions may be considered as an expression of chronic stimulation, triggered by CMV reacti-
vation rather than a malignant transformation.
Biol Blood Marrow Transplant 18: 1765-1770- (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: LGL, CMV, Stem cell transplant, GVHDINTRODUCTION
Large granular lymphocytes (LGLs) are immuno-
phenotypically heterogeneous lymphocytes. Immuno-
phenotypically, they can be either CD3-negative
natural killer cells (NK-LGL) or activated CD3-
positive cytotoxic T cells (T-LGL), the latter usually ac-
counting for less than 5%of all lymphocytes in a normal
peripheral blood [1]. Reactive expansions ofT-LGL can
occur within different situations such as autoimmune
diseases,underlyingmalignantneoplasms [2], viral infec-
tions [3], especially cytomegalovirus (CMV) infection
[4,5], or after therapy with tyrosine kinase inhibitors in
patients with chronic myeloid leukemia [6]. Reactive
T-LGL expansions are usually polyclonal, transient,
and asymptomatic. Neoplastic clonal proliferation of
T-LGL is classified asT cell large granular lymphocytic
leukemia in the World Health Organization classifica-Department of Hematology; and 2Department of Pathol-
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oi.org/10.1016/j.bbmt.2012.07.007tion [7,8]. T-LGL leukemia is characterized by a persis-
tent increase of the number of peripheral blood LGL,
usually between 2 to 20  109/L without a clearly iden-
tified cause [8]. However, it is now recognized that
a lower count (range, 0.4-2 109/L) may be compatible
with the diagnosis [9]. After allogeneic hematopoietic
stem cell transplant (HSCT), T-LGL expansions have
been described [10,11]; however, data about characteris-
tics and clinical outcome of patients with LGL
populations after allogeneic HSCT are still sparse.
Therefore, we aimed to evaluate frequency, clinical pre-
sentation, laboratory features, outcome, and risk factors
of patients with a persistent T-LGL population after al-
logeneic HSCT.METHODS
This was a single-center, cross-sectional study per-
formed at the Hematology Division of the University
of Basel, Switzerland. After allogeneic HSCT, all
recipients were regularly controlled at 1, 3, 6, and
12 months, and thereafter at yearly intervals or more
often when indicated. These consultations included
assessment of medical history, physical examination,
and laboratory tests, such as complete blood count
including morphological analysis of peripheral blood
cells, lymphocyte subpopulations, peripheral blood
chimerism, and blood chemistry. Bone marrow
1766 Biol Blood Marrow Transplant 18:1759-1770, 2012S. Nann-R€utti et al.(BM) investigation was performed regularly at 3 and 6
months, at 1, 2, and 5 years, and every 5 years thereaf-
ter. During the first 90 days after HSCT, additional
monitoring of immunosuppression and CMV replica-
tion using pp65 antigenemia or real-time PCR was
done as described in a previous study [12].
In this study, all postallogeneic HSCT recipients
who came to regular controls between January 1,
2008, and December 31, 2009, were consecutively
included. On control day, in accordance with our stan-
dards, previous blood counts were reviewed: if patients
showed persistent lymphocytes (.3 G/L for more
than 3 months) and abnormal CD4/CD8 ratios in the
lymphocyte subpopulations, defined as CD4/CD8
\1.0 or .1.5, and extensive immunophenotyping
of the peripheral blood cells was assessed. Flow cytom-
etry analyses were performed using the flow cytometry
system FACSCalibur (BD Biosciences, San Jose, CA).
The immunophenotyping of the lymphocytes
included the following antibody panel: CD2, CD3,
CD4, CD5, CD7, CD8, CD16, CD25, CD30,
CD56, CD57, HLA-DR, TCRab, and TCRgd.
T-LGL expansion was defined as an abnormal
T cell population type CD31, CD81, or CD41,
with expression of at least 1 of the NK markers
(CD16, CD57, or CD56), and with presence of
LGLs in peripheral blood films [13]. In all cases with
an abnormal expansion of T-LGL cells, a TCR gene
rearrangement from peripheral blood or BM was per-
formed (4 color multiplex PCR assay and automated
high-resolution fragment analysis on ABI 310 Genetic
Analyzer; Applied Biosystems, Foster City, CA).
We compared patients with T-LGL expansion to
the cohort of patients without LGL expansion, using
the chi-square test for categorical data and the
Mann-Whitney U test for continuous variables. Vari-
ables included into the analysis were age, sex, diagnosis
(malignant versus nonmalignant diseases), condition-
ing regimen (myeloablative versus reduced intensity
conditioning), total body irradiation (TBI), type of
donor, graft source, acute graft-versus-host disease
(aGVHD) or chronic GVHD (cGVHD), remission
status at control, and CMV reactivation. To identify
independent prognostic risk factors, a multivariate
stepwise linear regression analysis was performed. Dif-
ferences between the results of comparative tests were
considered significant if the 2-sided P value was\.05.
Statistical analysis was performed using SPSS statisti-
cal software (SPSS for Windows, Release 17, SPSS,
Inc., Chicago, IL).
Patients provided a written informed consent to
have their data on disease, treatment, and outcome
including late complications reported in an anonymous
way to the registry. Clinical surveillance of HSCT
recipients was approved by local institutional review
boards. Patient characteristics, HSCT conditioning
regimens, and clinical outcome data were collectedprospectively and stored in the local institution data-
base registry.RESULTS AND DISCUSSION
Within 215 post-HSCT evaluated patients, 14 (7%)
had an LGL expansion. Patients’ characteristics with and
without LGL expansion are summarized in Table 1. Pri-
mary disease, remission status, andHSCTcharacteristics
of patients with LGL expansion are detailed in Table 2.
The median time between HSCT and the beginning of
lymphocytes, and between HSCT to study time was 16
months (range, 3-58 months) and 56 months (range, 3-
159months), respectively.Themedian lymphocytecount
was 4.24 G/L (range, 3.0-26.5 G/L), and the
median count of the T-LGL population was 2.10 G/L
(range, 1.25-11.52 G/L) (Table 3). The median duration
of the lymphocyteswas31months (range, 2-179months).
The immunophenotyping in all these patients showed a
T-LGL proliferation. In 13 of 14 patients,
the following phenotype was found: CD31, CD81,
CD4-, CD21, CD51, CD71, and TCRab1. From
these 13 patients, 7 expressed CD161 CD571;
5 expressed CD571; and 1 expressed CD161, CD561
and, CD571. In 1 of the 14 patients, the population
was CD31, CD41, CD8-, additionally expressing
CD21, CD51, CD71, CD561, CD571, and
TCRab1. The TCR-g gene rearrangement examina-
tion was performed in all 14 patients (from peripheral
blood in 8 of 14 patients [57%]; and from BM in 6 of
14 patients [43%]). In 5 patients, clonality was found (1
patient showed biclonality). Detailed descriptions of pa-
tients’ characteristics with LGL expansion are summa-
rized in Table 3.
Neutrophil counts were normal in all patients with
LGL expansion. Eight of 14 patients (57%) showed
a mild hyporegenerative anemia. Thrombocytopenia
was present in 2 of 14 patients (14%) (1 associated
with graft rejection, and 1 associated with CMV
infection). Five of 14 recipients showed elevated
antinuclear antibodies, 4 of them with a slight increase
and 1 with a moderate increase. One patient had eleva-
ted rheumatoid factors, 2 patients had mild hypergam-
maglobulinemia, 3 patients had minimal M-gradient,
and 1 patient had amild positive polyspecific antiglobu-
lin test for IgGwithout clinical evidence of hemolysis, as
well as a monoclonal IgG l of 7 g/L.
At the time of diagnosis of LGL expansion,
1 patient had persistent disease (primary myelofibro-
sis) and the chimerism was recipient type. This pa-
tient never engrafted after umbilical cord blood
transplantation. The other 13 patients had a complete
hematological remission with 100% donor type chi-
merism in peripheral blood. One of these 13 patients
had a BCR-ABL1 molecular relapse of a B lympho-
blastic leukemia at study time. Three patients were
Table 1. Characteristics of Patients Treated with Allogeneic HSCT, Presenting with or without T-LGL
Total With T-LGL Expansion Without T-LGL Expansion P Value
No. of patients 215 14 201
Median age at HSCT, years (range) 41 (12-68) 38.5 (25-64) 41 (12-68) .835
Median age at follow-up, years (range) 48 (21-70) 45 (30-70) 48 (21-69) .519
Sex
Male 124 (58%) 7 (50%) 117 (58%) .548
Female 91 (42%) 7 (50%) 84 (42%)
Diagnosis
Malignant hematological diseases 202 (94%) 13 (93%) 189 (94%) .814
Aplastic anemia 10 (4%) 1 (7%) 9 (4%)
Autoimmune disease 3 (2%) 0 3 (2%)
Conditioning
Myeloablative 174 (84%) 11 (79%) 163 (85%) .528
Reduced intensity conditioning 32 (16%) 3 (21%) 29 (15%)
TBI
No TBI 61 (28%) 3 (21%) 58 (29%) .551
With TBI 154 (72%) 11 (79%) 143 (71%)
Donor
Matched related 139 (65%) 9 (64%) 130 (65%) .319
Matched unrelated donor 63 (29%) 3 (21%) 60 (30%)
Mismatched donor* 10 (5%) 2 (14%) 8 (4%)
Syngeneic sibling 3 (1%) 0 3 (1%)
Graft
Peripheral blood stem cells 159 (78%) 10 (72%) 149 (79%) .550
Bone marrow 43 (21%) 3 (21%) 40 (21%)
Cord blood 1 (1%) 1 (7%) 0
CMV reactivation
No 143 (73%) 5 (36%) 138 (76%) .001
Yes 52 (27%) 9 (64%) 43 (24%)
GVHD
aGVHD grade 0-1 112 (55%) 4 (29%) 111 (57%) .02
aGVHD grade 2-4 93 (45%) 10 (91%) 83 (43%)
No cGVHD 62 (29%) 4 (29%) 58 (29%) .610
cGVHD 150 (71%) 10 (71%) 140 (71%)
Remission status at control
Complete remission 92 (84%) 13 (93%) 79 (83%) .350
Not in complete remission 17 (16%) 1 (7%) 16 (17%)
Follow-up (days) 223 (92-971) 316 (195-658) 217 (92-971) .007
HSCT indicates hematopoietic stem cell transplant; T-LGL, T cell large granular lymphocyte; TBI, total body irradiation; CMV, cytomegalovirus; GVHD,
graft-versus-host disease; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.
*Inclusively cord blood donor.
Biol Blood Marrow Transplant 18:1759-1770, 2012 1767LGL Expansion after Allogeneic HSCTaffected by joint pain that had appeared previously
and was considered to be associated with cGVHD.
No patient showed palpable splenomegaly, and
none of them had typical signs or symptoms of an au-
toimmune disease. Previously mentioned cytopenias
were considered linked to transplant-related prob-
lems rather than associated with the LGL expansion.
BM biopsy was evaluable in 13 of 14 patients. The
majority of patients presented with a hypocellular
BM (7 of 13 patients); it was normocellular in 3 and
hypercellular in another 3 patients. The extension
of BM involvement through T cells was far less
than 50% of all cellular elements. None of the pa-
tients fulfilled the diagnostic criteria for LGL leuke-
mia according to the World Health Organization
classification [8]. None of the patients had an indica-
tion for therapy due to LGL expansion.
In univariate analysis, patients with LGL pre-
sented more often with a history of CMV reactivation
(P 5 .001) and of aGVHD (P 5 .02), when compared
with patients without LGL. In multivariate analysis,CMV reactivation (relative risk [RR]: 5.063; 95%
confidence interval [CI]: 1.586-16.160; P 5 .006),
but not aGVHD (RR: 2.831; 95% CI: 0.831-9.648;
P 5 .096), showed a significant association with
LGL expansion. Age of the patient, conditioning reg-
imen, donor type, graft source, and initial diagnosis
as well as relapse after HSCT were not related to
T-LGL expansion.
Our data show that persistent LGL expansion
after allogeneic HSCT is not a rare finding and ap-
pears in nearly 1 of 10 patients during the follow-
up. In contrast, reports on LGL expansion after
autologous HSCT are scarce [14]. Patients with
LGL expansion were clinically asymptomatic, despite
showing discrete biological changes. The high fre-
quency of LGL expansions after HSCT is consistent
with the unique previous series published by Mohty
et al. [15], with 6 cases of LGL expansion in a cohort
of 201 patients. However, Mohty et al. [15]
showed different findings with respect to clinical
presentation. Indeed, 4 of 6 patients with T-LGL
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1768 Biol Blood Marrow Transplant 18:1759-1770, 2012S. Nann-R€utti et al.expansions had relevant clinical signs such as cytope-
nia with septicemia, polyarthritis, or granulomatous
hepatitis. In solid organ transplant setting, T-LGL
expansion is even more frequent. It was reported in
18 of 23 solid organ transplant recipients, without
signs of rejection, infection, or signs of T-LGL leu-
kemia [16]. As for our cohort, T-LGL
expansions, even of clonal origin, were without clini-
cal manifestations.
In treated CMV infection, clonal expansion of
T-LGL can last up to several months [4]. After solid
organ transplant with CMV infection, an LGL
expansion may appear more than 6 months later and
persist up to several years [17]. These data are
consistent with our finding that there was a correlation
between CMV reactivation and LGL expansion even
in patients with a very long-term follow-up. Thus, 7
of 9 patients with LGL expansion cleared the virus
at study time. Two of 9 patients had multiple
reactivation of viral replication along the post-HSCT
follow-up time. Seven of 9 patients needed therapy
to control the replication. One patient had CMV
colitis. The median time between the last positive rep-
lication and the study time was 56 months (range,
0-159 months).
Data from the literature about the relationship
between CMV reactivation, GVHD, and LGL expan-
sion after allogeneic HSCT are conflicting. Some of
them described an association of T-LGL with CMV
infection and GVHD [18], whereas other data showed
only an association with CMV infection [19]. In our
cohort, LGL expansion was associated with CMV rep-
lication but not with aGVHD. All patients were classi-
fied as LGL expansions and not as T cell LGL
leukemia. At first, this seems to be in contradiction
with a number of case reports on T-LGL leukemia af-
ter HSCT [7,20-25]. Our results cannot exclude that
LGL expansion may rarely evolve into T-LGL leuke-
mia after HSCT. However, these cases remain the ex-
ception compared to the relative high number of
patients with T-LGL expansions.
In conclusion, we observed T-LGL expansion
in 7% of a large cohort of post-HSCT survivors.
The majority of the LGL expansions presented
with a CD31/CD81 phenotype, and 36% had
a clonal TCR gene rearrangement. Regardless of
clonality, all patients were clinically asymptomatic
with respect to T-LGL expansion. Our data indicate
that, even if monoclonal, posttransplantation T-LGL
expansion may be considered as an expression of
chronic stimulation triggered by CMV reactivation
rather than the result of a malignant transformation.
Whether the presence of LGL expansion is the
expression of a balanced chronic immune response
with a possible graft-versus-leukemia effect after allo-
geneic HSCT should be evaluated in a larger cohort
of patients.
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